Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06996886 · ClinicalTrials.gov registry record · Phase 1

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT06996886 is a Phase 1 study of Healthy Participants that has completed, run by AstraZeneca. The registered enrollment target is 16 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06996886, a Phase 1 study of Healthy Participants, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.

Conditions Studied

Interventions

  • DRUG AZD5004

Study Locations (1)

Maryland

  • Research Site - Baltimore

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2025-05-22
Est. Completion 2025-07-25
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT06996886

The ClinicalTrials.gov registry entry for NCT06996886 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (75% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which AZD5004 is the first listed.

NCT06996886 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT06996886 about?

NCT06996886 is a clinical study titled "A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations". The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.

What is the current status of trial NCT06996886?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-05-22. Estimated completion is 2025-07-25.

What conditions does trial NCT06996886 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT06996886?

The interventions under investigation include: AZD5004 (DRUG).

Who is sponsoring clinical trial NCT06996886?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06996886 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.